TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC
Both intrinsic and acquired resistance to poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as a formidable challenge in clinical practice. Here, we report that the transcription factor E-twenty-six (Ets)-related gene ( ERG ) was highly expressed in PARPi-resistant prostate cancer and was correlated with PARPi resistance in castration-resistant prostate cancer (CRPC) cells. ERG was posttranslationally modified by tripartite motif-containing 28 (TRIM28) as SUMOylation at lysine 389 (K389), which promotes DNA homologous recombination repair (HRR), thereby weakening the efficacy of PARPis. Mechanistically, the SUMOylation of ERG (K389) inhibited protein degradation mediated by the SPOP-mediated ubiquitin-proteasome pathway, thereby stabilizing the protein. Concurrently, this posttranslational modification increased HRR capacity by inhibiting 53BP1 expression, which in turn reduced PARPi sensitivity. Blockade of ERG K389 SUMOylation can effectively impair DNA repair efficacy and overcome PARPi resistance. These findings suggest that TRIM28-mediated ERG SUMOylation conveys resistance to PARPis by inhibiting 53BP1 expression; combined TRIM28/ERG targeting and PARPi therapy may improve outcomes for ERG-positive CRPC patients.
Authors
- Yongqing Zhang (ORCID: https://orcid.org/0000-0002-6980-1848)
- Zhong-Yuan Wang (ORCID: https://orcid.org/0000-0002-0257-8450)
- Zhi Shang (ORCID: https://orcid.org/0000-0002-6189-6301)
- 洪宗元 (ORCID: https://orcid.org/0009-0003-9313-0700)
- Bo Dai (ORCID: https://orcid.org/0000-0003-1383-3864)
- Zhe Hong (ORCID: https://orcid.org/0000-0001-5942-4893)
- Guo-Wen Lin (ORCID: https://orcid.org/0009-0005-6898-0441)
- Shiwei Liu (ORCID: https://orcid.org/0000-0002-1901-3296)
- Yuchen Jiang (ORCID: https://orcid.org/0009-0002-3577-9598)
- Chenye Jiang (ORCID: https://orcid.org/0009-0003-7015-3694)
- Zheng Liu (ORCID: https://orcid.org/0009-0003-7691-5266)
- Runkai Zhang (ORCID: https://orcid.org/0009-0004-1209-9885)
Institutions
- Wannan Medical College (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Science Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/sciadv.aec9042
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- National Health Commission of the People's Republic of China
- Bijzonder Onderzoeksfonds UGent